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Abstract
Growing evidence has shown that skeletal muscle secretes several bioactive proteins from within the cell 
into extracellular fluid. The secretion of several proteins, whose levels increase in response to exercise, can 
regulate the functions of several organs via autocrine and paracrine actions, and mediate exercise-induced 
benefits such as metabolic improvement, anti-inflammation, and muscle building; this is known as the myokine 
theory. In addition, we found a novel muscle-secreted protein, secreted protein acidic and rich in cysteine 
(SPARC), a secreted matricellular glycoprotein. The muscle-secreted protein SPARC can support underlying 
mechanisms of epidemiological studies that suggest that regular exercise can prevent the incidence of colon 
cancer. Many different types of studies have suggested that many other proteins secreted from muscle have yet 
to be identified. In addition to the proteins, non-coding small RNA in exosome and metabolites which generate 
in process of nutrients metabolism with muscle contraction are also suggested to be secretory bioactive factors. 
These secretory factors may be biomarkers that reflect muscular function and beneficial adaptation achieved by 
exercise training, and could estimate adequate condition of exercise to obtain its beneficial effects. 
Introduction 
Skeletal muscles support physical activity and generate 
large energy with muscle contraction.  In addition, these 
muscles release various metabolic factors such as lactate, 
amino acids, and ammonia into circulation in response 
to physiological changes. Growing evidence has shown 
that muscle cells secrete also bioactive proteins, which 
have regulatory role in the muscles and other organs via 
endocrine, autocrine, or paracrine actions; this is the so-
called myokine theory [1]. These secreted proteins are 
elevated in response to exercise and suggested to mediate 
acute and chronic effects obtained by exercise (Table 1). 
Adequate regular exercise has numerous health 
benefits. In the last few decades, epidemiological studies 
have shown that dietary–exercise regimen reduces the 
risk of various common diseases such as type 2 diabetes, 
cardiovascular disease, and carcinogenesis. In addition, 
regular exercise improves the prognosis of existing 
diseases, including diabetes, ischemic heart disease, 
heart failure, and chronic obstructive pulmonary disease. 
Accumulating evidence has demonstrated the mechanisms 
underlying the benefits of acute and regular exercise. 
A single bout of exercise drastically changes various 
physiological parameters such as hormone production, 
blood flow, and the activity of the nervous and immune 
system, in addition to altering the expression/activity of 
certain genes and proteins in the skeletal muscle. Further, 
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regular exercise adaptively improves normal bodily 
functions including energy metabolism, muscle strength, 
brain-nervous system, endocrine system, and immune 
function, even in resting state, and the expression/activity 
of several key proteins in the skeletal muscle is involved in 
the development of this adaptation. The bioactive proteins 
secreted from the muscle would contribute in promoting 
health benefits along with maintaining physiological 
homeostasis and sports performance during exercise.
Metabolic and immune functions of 
muscle-secreted proteins
Previously, several proteins that are secreted from muscle 
cells into the extracellular environment in response to 
exercise have been reported. Many of them were suggested 
to be involved in the regulation of metabolic function 
in skeletal muscle itself and also in other metabolic 
organs. Interleukin (IL) -6 is a well-known secretory 
protein that is transiently elevated in muscles following 
a single bout of exercise [2]. IL-6 may act locally within 
the contracting skeletal muscle in a paracrine manner 
or be released into the circulation; it may increase up to 
100-fold thus, inducing systemic effects [3, 4]. While 
it is controversial, IL-6 elevated by exercise in skeletal 
muscle can lead to additional improvement of insulin 
sensitivity in response to exercise [5]. Previous studies 
also showed that infusion of recombinant-IL-6 at the 
normal physiological level selectively stimulates lipid 
metabolism in skeletal muscle in healthy subjects [6] 
and in subjects with type 2 diabetes [7]. In addition, it 
has been suggested that muscle-derived IL-6 plays a role 
in up-regulation of lipolysis in adipose tissue through 
an endocrine mechanism [4]. In fact, recombinant IL-6 
intra-lipid infusion elevates plasma fatty acid levels 
due to lipolysis of adipose tissue in healthy humans [8]. 
Furthermore, injection of IL-6 to rats catabolizes hepatic 
glycogen and accelerates glucose output into circulation 
[9], which may contribute to the maintenance of blood 
glucose and supply the required energy substrate during 
exercise. In addition, physiological elevation of IL-6 
levels stimulates an insulin secretory hormone glucagon-
like peptide-1, from intestinal L cells and pancreatic alpha 
cells, which ultimately improves insulin secretion from 
pancreatic β cells [10].
In addition to IL-6, other muscle-secreted proteins 
such as brain-derived neurotrophic factor, fibroblast 
growth factor 21, IL-15, and myonectin have been shown 
to be produced in skeletal muscle in response to acute or 
chronic exercise, and have been suggested to increase fat 
oxidation or glucose uptake in skeletal muscles [11-16]. A 
more recent study showed that peroxisome proliferator-
activated receptor gamma coactivator-1 alpha (PGC-1α) 
expression in skeletal muscle stimulates an increase in 
Table 1. Bioactive proteins secreted from skeletal muscle in response to exercise.
Protein Function Target organs References
IL-6 Glucose metabolism, Lipid metabolism, 
Insulin secretion, Anti-inflammation
Skeletal muscle, Adipose tissue, 
Liver, Intestine, Neutrophils
[3] [4] [5] [6] [7] [8] 
[9] [20] [22] [25]
IL-7 Muscle hypertrophy Skeletal muscle [51]
IL-15 Glucose metabolism, Lipid metabolism, 
Muscle hypertrophy
Skeletal muscle [14] [15] [46] [49]
BDNF Glucose metabolism Skeletal muscle [11]
FGF-21 Glucose metabolism Skeletal muscle, Liver, Adipose tissue [12] [13]
Myonectin Lipid metabolism Adipose tissue, Liver [16]
Irisin Lipid metabolism Adipose tissue [17]
LIF Muscle hypertrophy Skeletal muscle [42] [44]
IGF-1 Muscle hypertrophy, Osteogenesis Skeletal muscle, Bone [26] [33]
Fst/Fstl-1 Muscle hypertrophy, Endothelial function Skeletal muscle, Endothelium [36] [39]
Myostatin Muscle anti-hypertrophy Skeletal muscle [35] [38]
Oncostatin M Anti-tumorigenesis Breast [85]
SPARC Anti-tumorigenesis Colon [52]
IL-6 - interleukin 6; IL-7 - interleukin 7; IL-15 - interleukin 15; BDNF – brain-derived neurotrophic factor; FGF-21 – fibroblast grown factor; 
LIF – leukemia inhibitor factor; IGF-1 – insulin like growth factor; Fst – follistatin; Fstl-1 – follistatin-like 1; SPARC – secreted protein acidic 
and rich in cysteine. 
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the expression of FNDC5, a membrane protein that is 
cleaved and secreted as Irisin [17]. PGC-1α has been 
shown to play a central role in a family of transcriptional 
co-activators involved in aerobic metabolism; thus, a 
considerable amount of attention has been focused to it 
as a target for the prevention or treatment of metabolic 
syndrome through activation of lipid metabolism. Acute 
and regular exercise elevates PGC-1α expression in 
skeletal muscle [18, 19] and, consequently, the secretion 
of Irisin from the muscle into circulation. Secreted Irisin 
acts on white adipose cells and facilitates brown-fat-like 
development, which may account for metabolic rate (or 
metabolism) elevation and body fat reduction induced by 
exercise.
Anti-inflammation is another function suggested for 
muscle-secreted proteins, and muscle-derived IL-6 likely 
contributes to reduce inflammation when in circulation 
[2]. IL-6 can increase the levels of anti-inflammatory 
factors such as IL-10, IL-1 receptor agonist, and 
C-reactive protein in neutrophiles and the liver [20, 21]. 
Indeed, recombinant IL-6 infusion inhibits the endotoxin-
induced increase in circulating levels of tumor necrosis 
factor-alpha (TNF-α), a representative pro-inflammatory 
cytokine [22]. On the other hand, IL-6 is recognized as a 
pro-inflammatory cytokine. In severe systemic infection, 
circulating IL-6 is drastically elevated and may reach over 
10000-fold the level in resting healthy state. In contrast, 
chronic low-grade elevation of IL-6 (below 10-fold of 
that in resting healthy state) is induced by sedentary life, 
obesity, and dietary habits, which are associated with 
the development of metabolic diseases, although regular 
physical activity reduces the elevation of circulating IL-6 
in resting state along with metabolic improvement [23, 
24]. Therefore, it is necessary to distinguish between the 
exercise-induced secretion of IL-6, which is a transient/
moderate elevation, and the pathological states, which are 
transient/high or chronic/low elevations.  
Myogenic function of muscle-secreted 
protein 
Several proteins contribute to muscle hypertrophy via 
autocrine or paracrine effects. Insulin growth factor-1 
(IGF-1) is known as a major hypertrophic inducer. It has 
been considered for long time that IGF-1 is generated by 
stimulating growth hormone in liver and secreted into 
circulation [25]. In addition, IGF-1 could be generated by 
muscle itself in response to exercise and acts in autocrine 
and paracrine manners [26]. The secreted IGF-1 binds 
to its receptor on the plasma membrane of muscle cells 
and activates several intracellular signaling pathways 
including mitogen-activated protein kinase signaling, 
phosphatidylinositol 3-kinase (PI3-K)/Akt signaling, 
and calcineurin signaling, which promote proliferation, 
differentiation, survival, and protein synthesis of muscle 
cells [27-30]. In human, there are three different IGF-1 
isoforms consisting of IGF-1 Ea, IGF-1 Eb, and IGF-1Ec, 
which is also known as mechano-growth factor [31]. It 
has been suggested that these isoforms may accelerate 
the effect of IGF-1 and may also play a role in muscle 
hypertrophy independent of IGF-1 [32]. Furthermore, the 
secreted IGF-1 may also function as an osteogenic factor 
in bone by stimulating differentiation and mineralization 
[33].  
Myostatin, a member of the transforming growth 
factor-β family, is a negative regulator of muscle 
hypertrophy. Originally, although myostatin is recognized 
to affect to the intracellular signaling such as calcineurin 
pathway [34], it is also secreted into extracellular fluid 
and also acts in an autocrine manner [35]. In contrast, 
follistatin, an antagonist of myostatin, attenuates the 
inhibitory effect of muscle growth [36]. The secreted 
myostatin and follistatin mediate proliferation and 
differentiation of muscle cells regulated by exercise [37, 
38]. A follistatin family protein follistatin-like 1 (Fstl1) 
in skeletal muscle is increased by Akt activation during 
muscle hypertrophy, and enhances differentiation and 
migration, as well as inhibits apoptosis, of endothelial cells 
in muscle tissue in a paracrine manner [39]. Exogenous 
Fstl1 improves endothelial function and induces 
revascularization by activating endothelial nitric oxide 
synthase [39]. Leukaemia inhibitory factor (LIF), one of 
IL-6 super family, induces proliferation of satellite cells 
by activating a signaling cascade involving Janus kinase 
1, signal transducer and activator of transcription (STAT) 
1, and STAT3 [40, 41]. In addition, Hunt et al. [42] found 
that LIF treatment significantly reduced staurosporine-
induced apoptotic DNA fragmentation and also reduced 
the proteolytic activation of caspase-3 compared to 
controls. This apoptosis-inhibiting role of LIF was 
completely abolished by inhibiting PI3-K/Akt pathway. 
Therefore, LIF secreted by muscle contraction appears 
to increase the number of satellite cells by promoting 
proliferation and blocking apoptosis in autocrine and 
paracrine manners [42-44].    
IL-15 is also known as a muscle-secreted protein 
which can regulate muscle mass via inhibiting protein 
degradation and accelerating differentiation [45, 46]. 
Muscle IL-15 is elevated by a single bout of exercise in 
human [47], although it is controversial if circulating IL-
15 is also increased [15, 48]. On the other hand, muscle 
and serum IL-15 levels decline progressively with age and 
unloading atrophy in rodents [49, 50]. More recently, IL-7 
was coexpressed with myosin heavy chain in differentiated 
muscle cells and secreted into extracellular fluid [51]. 
IL-7 accelerates myogenesis and migration of satellite 
cells during muscle development. It has been shown 
that strength training for 11 wk increased expression 
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Figure 1. A single bout of exercise increases circulating levels of SPARC in humans. Time course of serum SPARC level after 
steady-state cycling at 70% maximal oxygen uptake (VO2max) for 30 min (n = 10). 
*P < 0.05 versus resting state (Rest).
*Significant difference between resting state (Rest) and immediately after exercise (Post-Ex) are depicted by (*) for P < 0.05. 
Results are shown as mean ± standard error. Data from Aoi et al. [52].
of IL-7 in muscles obtained from human subjects [51], 
which suggests that secreted IL-7 contributes to muscle 
adaptation during the training via autocrine or paracrine 
actions. 
SPARC is a cancer preventive protein 
secreted by skeletal muscle
We recently tried to identify novel muscle-derived 
proteins that are secreted into the general circulation. The 
transcriptome of muscle tissue in sedentary and exercised 
young and old mice were compared. In total, 381 genes 
in gastrocnemius muscle were up-regulated in mice that 
exercised for 4 weeks compared with sedentary mice; 
on the other hand, 100 genes were downregulated in 
24-month-old sedentary mice compared with 3-month-
old sedentary mice [52]. Among these genes, there 
were 24 common genes which increased by exercise 
and decreased by aging, including the protein secreted 
protein acidic and rich in cysteine (SPARC), a secreted 
matricellular glycoprotein. The level of SPARC protein in 
gastrocnemius muscle was significantly elevated, and the 
elevation of muscle SPARC was found to be specifically 
pronounced around the plasma membrane in exercised 
mouse muscle cells [52]. In a human study, a time-course 
analysis of the serum levels of SPARC showed that the 
protein was elevated in young healthy men immediately 
after a single bout of cycling exercise, and then gradually 
decreased until it returned to the baseline level 6 h after 
exercise [52] (Figure 1). This exercise-induced increase 
in SPARC level appeared to be muscle specific, because 
no increase was observed in other organs where SPARC 
is abundant, such as adipose tissue, testis, liver, and 
colon, in a mouse experiment. Furthermore, 60 min 
cyclic stretching of C2C12 myotubes stimulated SPARC 
secretion into the extracellular medium. These findings 
suggest that a single bout of exercise accelerates SPARC 
secretion from contracting muscle into blood. 
A number of epidemiological studies have focused on 
the relationships between the average individual’s level 
of physical activity and the incidence of cancer in Europe, 
the United States, and Japan. The general consensus 
among the authors of these studies is that physical activity 
can prevent cancer in the colon, breast, uterus, pancreas, 
and lungs [53-59]. In particular, almost all investigations 
clearly demonstrated that physical activity significantly 
reduces the incidence of colon cancer. A review of these 
epidemiological studies by The World Cancer Research 
Fund/United States Cancer Research (WCRF/AICR) 
showed that physical activity was the only lifestyle change 
that would certainly reduce an individual’s risk of colon 
cancer [60]. Although the exact mechanism underlying 
the beneficial results obtained in epidemiological studies 
remains unclear, various potential mechanisms such as 
activation of the immune system and antioxidant status, 
anti-inflammation, improved insulin sensitivity and 
proportion of bile acids, and exercise-induced increases 
in gastrointestinal transit have been suggested [61-66]. 
Previously, we reported that regular exercise prevents 
the formation of aberrant crypt foci (ACF), which are the 
precursor lesions of colon adenocarcinoma, associated 
with anti-inflammation on the mucosal surface of the 
mouse colon [67]. However, the endogenous defense 
system, such as antioxidant and chaperone proteins, 
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Figure 2. SPARC prevents tumorigenesis in colon. The numbers of aberrant crypt foci (ACF) on the mucosal surface of the colon 
were counted under a light microscope. In wild-type mice, regular low-intensity exercise significantly reduced the number of ACF 
in the colons of AOM-treated mice compared to sedentary mice. In contrast, more ACF were formed in AOM-treated SPARC-null 
mice than in wild-type mice, and exercise did not have an inhibitory effect. Results are shown as mean ± standard error (n = 10–12). 
AOM, AOM-treated sedentary mice; AOM-Ex, AOM-treated exercised mice. *P < 0.05 and ** represents P < 0.01. Data from Aoi 
et al. [52].
was unchanged [67], which suggested that the anti-
tumorigenesis effect of regular exercise is affected by 
the levels of circulating factors rather than endogenous 
proteins in the colon.
SPARC is a matricellular protein that is primarily 
involved in development, remodeling, and tissue 
repair through modulation of cell-cell and cell-matrix 
interactions [68-70]. In addition, SPARC has been 
reported to have more unique functions such as regulating 
angiogenesis and collagen production/fibrillogenesis, 
chaperoning, inhibiting adipogenesis, and further 
exerting anti-tumorigenetic effects [71-77]. Previous 
studies have revealed that a lack of SPARC increases 
pancreatic and ovarian tumorigenesis in vivo [76, 77]. 
In addition, the presence of exogenous SPARC in cancer 
cell lines reduces cell proliferation in vitro [77, 78]. 
Furthermore, epigenetic silencing of the SPARC gene 
via hypermethylation of its promoter is frequent in colon 
cancers, which leads to rapid progression of the tumor 
[79, 80]. Moreover, modulation of SPARC expression 
affects the sensitivity of colorectal tumors to radiation 
and chemotherapy [81-83]. Interestingly, a clinical study 
showed that the 5-year survival of patients with tumors 
that expressed high levels of SPARC was significantly 
better than that of those with tumors that did not express 
SPARC [80]. Therefore, we examined the effect of the 
myokine SPARC on the onset of colon tumors by using 
SPARC-null mice. In a mouse model for colon cancer 
generated azoxymethane (AOM), regular low-intensity 
exercise, which consisted of treadmill running 3 times/
week for 6 weeks, significantly reduced the formation of 
ACF in the colons of wild-type mice [52] (Figure 2). In 
contrast, more ACF were found in AOM-treated SPARC-
null mice than in wild-type mice, and exercise did not 
have an inhibitory effect. Additionally, we examined the 
effect of exogenous SPARC on ACF formation in the 
colon by injection of recombinant SPARC in the AOM-
treated mice. Injection of SPARC, which is equivalent 
to the elevation in response to exercise, suppressed ACF 
formation. Furthermore, in a cell culture experiment, 
addition of recombinant SPARC to colon carcinoma 
cells inhibited cell proliferation in a dose-dependent 
manner. In contrast, addition of conditioned medium 
from SPARC short interfering RNA -treated muscle cells, 
accelerated the proliferation of the carcinoma cells. These 
results suggested that secreted SPARC suppresses colon 
tumorigenesis, which is consistent with the findings of 
many previous studies [73-76, 79] demonstrating that 
SPARC is a tumor suppressor.
A cause of ACF formation is dysregulation of apoptosis 
[84]. The terminal deoxyribonucleotidyl transferase 
dUTP nick end labeling (TUNEL) assay showed that 
regular exercise increased the number of apoptotic colon 
cells in wild-type mice; however, the number did not 
differ between sedentary and exercised SPARC-null mice 
[52]. Furthermore, the levels of cleaved caspase-3 and -8 
were higher in wild-type mice than in SPARC-null mice, 
and regular exercise further increased the levels of these 
apoptosis markers in wild-type mice but not in SPARC-
null mice. These findings suggested that SPARC mediates 
the reduction of exercise-induced colon tumorigenesis 
via caspase-3- and caspase-8- dependent apoptosis 
(Figure 3). In addition, we found the effect of exogenous 
SPARC on colon tumor by using colon carcinoma cells, 
and found that apoptosis of these cells was elevated by 
addition of recombinant SPARC in a dose-dependent 
manner. This in vitro result supported the hypothesis that 
SPARC prevents proliferation of colon tumor cells via 
increased apoptosis. In addition to SPARC, Hojman et 
al. [85] showed that oncostatin M, which is known as 
a tumor suppressor, could be secreted from contracting 
muscle into circulation in response to exercise. The 
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secreted-protein suppresses proliferation of mammary 
tumor cells via increasing caspase activity, which may 
be one of mechanisms of cancer prevention induced 
by habitual exercise. Taken together, the concept that 
muscle-secreted proteins contribute cancer prevention 
ought to be developed future.
Prospective
Many studies have suggested that there are muscle-secreted 
proteins yet to be identified. For example, a bioinformatics 
study showed that the secretome of human muscle cells 
includes more than 300 proteins [86]. In addition, an in 
vitro study demonstrated that myocytes secrete many 
proteins into the medium during differentiation [87, 88]. 
Furthermore, transcriptome and proteome studies of 
human and rodent muscle tissue have demonstrated that 
the expression of many genes and proteins increases in 
response to exercise [89-92]. Therefore, there are likely 
to be more unknown bioactive proteins which are secreted 
from muscle into extracellular fluid. 
It is well-known from previous studies that exercise 
releases various metabolic factors from skeletal muscle 
into circulation. For example, lactate is generated from 
carbohydrates via glycolytic metabolism and the amount 
is based on the intensity of exercise. After its release into 
blood, lactate is carried to other tissues and is utilized as 
a substrate of aerobic metabolism or gluconeogenesis. 
Recently, studies into further functions of lactate have 
shown that exogenous lactate mediates insulin-induced 
anti-lipolytic effect via G-protein coupled receptor GPR81 
located on plasma membrane [93], and also induces 
mitochondria biogenesis associated with activating 
Figure 3. Schematic of colon cancer prevention induced by exercise via the muscle-secreted protein SPARC. Exercise accelerates 
SPARC secretion from contracting muscle into blood in response to muscle contraction. The secreted SPARC increases the cleaved 
forms of caspase-8 and -3 and inhibits proliferation with apoptotic effect of colon cancer cells. It is suggested that colon cancer 
prevention induced by regular exercise is mediated by the muscle-secreted protein SPARC.
inflammatory and redox-sensitive signaling [94], which 
suggests that lactate acts as a signaling factor in muscle 
cells via autocrine and paracrine manner. In addition to 
lactate, other muscle-mediated metabolites including 
amino acids, ions, and ammonium, should be reconsidered 
as endocrine bioactive factors. In addition, microRNAs 
(miRNAs) may be secreted from muscle into circulation 
and function in an endocrine manner. Some miRNAs 
are taken into intracellular vesicles (e.g. exosomes) and 
released into circulation without being degraded by RNase 
[95]. In addition, the circulating miRNAs (c-miRNAs) can 
move from circulation into other cells and regulate their 
functions via regulation of gene expression at the post-
transcriptional level through translational inhibition or 
mRNA degradation. Several miRNAs are highly enriched 
in skeletal muscle [96-99] and may be secreted from muscle 
into circulation. In the future, many other muscle-secreted 
bioactive factors including metabolites and miRNA could 
be identified, which may accelerate the understanding of the 
effect of exercise on improvement of physical performance 
and prevention of diseases, and also estimates adequate 
condition of exercise to obtain its beneficial effects. 
Conclusion
Skeletal muscle secretes several bioactive proteins from 
within the cell into extracellular fluid. The secretion of 
several proteins, whose levels increase in response to 
exercise, can mediate exercise-induced benefits such as 
metabolic improvement, anti-inflammation, and muscle 
hypertrophy. We recently found a novel muscle-secreted 
protein SPARC which may be fundamental for the 
colon cancer prevention mechanism of regular exercise, 
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demonstrated by various epidemiological studies. Many 
other proteins, along with c-miRNAs in exosome and 
metabolites, secreted from muscle have yet to be identified. 
In the future, the presence and beneficial function of more 
unknown bioactive factors are expected to be discovered, 
which strengthens the development of sports science. 
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